Surgery – Instruments – Light application
Reexamination Certificate
2005-09-13
2005-09-13
Farah, A. (Department: 3739)
Surgery
Instruments
Light application
C606S005000, C607S089000, C128S898000
Reexamination Certificate
active
06942655
ABSTRACT:
Age-related macular degeneration (AMD) results in the formation of new blood vessels in the eye. The walls of these vessels leak fluid, which causes scarring in the surrounding tissue and results in reduced vision or loss of vision. Photodynamic therapy (PDT) alone has been used to treat AMD, but many retreatments are needed, which cause further damage to the already diseased area. Laser treatment to coagulate the fluid actually causes additional new vessels to form. However, the inventive method of treating patients with both PDT and scatter threshold laser coagulation therapy surprisingly either improved vision, or prevented further loss of vision. Moreover, the combined treatment eliminated the need for retreatment, and did not generate new vessel growth. Threshold laser coagulation and PDT may be administered within the same treatment session or either may be administered first and the other may be administered within ninety days.
REFERENCES:
patent: 5633275 (1997-05-01), Mori et al.
patent: 6162242 (2000-12-01), Peyman
patent: 2002/0165525 (2002-11-01), Nakamura
patent: 2003/0171320 (2003-09-01), Guyer
patent: 2004/0002694 (2004-01-01), Pawlowski et al.
patent: WO01/26591 (2001-04-01), None
patent: WO01/39764 (2001-06-01), None
The Choroidal Neovascularization Prevention Trail Group “Laser Treatment in Eyes with Large Drusen: Short-term Effects Seen in a Pilot randomized Clinical Trial,” Arch. Ophthalmol., Feb., 2001; 119: 198-207.
Exhibit A “The latest research on photodynamic therapy for macular degeneration,” American Federation for Aging Research, Apr. 3, 2003, www.infoaging.org/d-macu-6-r-photodynamic.html.
Ciulla et al.,Presumed Macular Choroidal Watershed Vascular Filling, Choroidal Neovascularization, and Systemic Vascular Disease in Patients With Age-related Macular Degeneration,American Journal of Ophalthmology, vol. 126, No. 1, 153-155, Jul. 1998.
Ciulla et al.,Color Doppler Imaging Discloses Reduced Ocular Blood Flow Velocities in Nonexudative Age-related Macular Degeneration,American Journal of Ophthalmology, vol. 128, No. 1, 75-80, Jul. 1999.
Friedman et al.,Ocular Blood Flow Velocity in Ager-related Macular Degeneration,Ophthalmology, vol. 102, No. 4, 640-646, Apr. 1995.
Friedman, A Hemodynamic Model of the Pathogenesis of Age-related Macular Degeneration, American Journal of Ophthalmology, Editorial, vol. 124, No. 5, 677-682, Nov. 1997.
Glaser et al.,Feeder Vessel Treatment for Age-related Macular Degeneration (AMD) with Classic Choroidal Neovascularization (CNV),Association for Research in Vision and Ophthalmology Annual Convention, Ft. Lauderdale, Florida, Abstract #1243-B556, May 2001.
Glaser and Murphy,High-Speed ICG Choroidal Angiography,Review of Ophthalmology, 110-112, Sep. 2000.
Grunwald et al.,Foveolar Choroidal Blood Flow in Age-Related Macular Degeneration,Investigative Ophthalmology & Visual Science, vol. 39, No. 2, 385-390, Feb. 1998.
Johnson et al.,A Potential Role for Immune Complex Pathogenesis in Drusen Formation,Experimental Eye Research, vol. 70, No. 4, 441-449, Apr. 2000.
Klingel et al.,Rheopheresis: Rheologic, Functional, and Structural Aspects,Therapeutic Apheresis, vol. 4, No. 5, 348-357, 2000.
Lip et al.,Age-related Macular Degeneration is Associated with Increased Vascular Endothelial Growth Factor, Hemorheology and Endothelial Dysfunction,vol. 108, No. 4, 705-710, Apr. 2001.
Maguire et al.,Laser Treatment in Eyes with Large Drusen,Ophthalmology, vol. 105, No. 1, 11-23, Jan. 1998.
Mainster et al.,Transpupillary Thermotherapy for Age-Related Macular Degeneration: Long-Pulse Photocoagulation, Apoptosis, and Heat Shock Proteins,Ophthalmic Surgery and Lasers, vol. 31, No. 5, 359-373, Sep./Oct. 2000.
Mullins et al.,Structure and composition of drusen associated with glomerulonephritis: Implications for the role of complement activation in drusen biogenesis,Eye, vol. 15, Part 3, 390-395, Jun. 2001,
Mullins et al.,Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease,FASEB Journal, vol. 14, No. 7, 835-846, May 2000.
Peyman et al.,Verteporfin Ocular Photodynamic Therapy Combined with Macular Scatter Photocoagulation for Occult or Predominantly Occult Subfoveal Neovascularization in Age-Related Macular Degeneration,Association for Research in Vision and Ophthalmology, Abstract, Tracking No. 02-A-2170, Dec. 7, 2001 (2 pages).
Piguet et al.,Evolution of Age-related Macular Degeneration with Choroidal Perfusion Abnormality,American Journal of Ophthalmology, vol. 113, 657-663, Jun. 1992.
Reichel et al.,Transpupillary Thermotherapy of Occult Subfoveal Choroidal Neovascularization in Patients with Age-related Macular Degeneration,Ophthalmology, vol. 106, No. 10, 1908-1914, Oct. 1999.
Ross et al.,Presumed Macular Choroidal Watershed Vascular Filling, Choroidal Neovascularization, and Systemic Vascular Disease in Patients with Age-Related Macular Degeneration,American Journal of Ophthalmology, vol. 125, No. 1, 71-80, 1998.
Smith et al.,Smoking and Age-Related Maculopathy: The Blue Mountains Eye Study,Archives in Ophthalmology, vol. 114, 1518-1523, Dec. 1996.
Vingerling et al.,Age-related Macular Degeneration is Associated With Atherosclerosis,American Journal of Epidemiology, vol. 142, No. 4, 404-409, 1995.
Zhao et al.,Delayed macular choriocapillary circulation in age-related macular degeneration,International Ophthalmology, vol. 19, 1-12, 1995.
POSTER, “Combined Verteporfin Ocular Photodynamic Therapy with Macular Scatter Photocoagulation for Occult Subfoveal Neovascularization in ARMD”, Gholam Peyman, et al., Retina Congress, Sep. 28-Oct. 2, 2002.
Verteporfin in Photodynamic Study Group,Verteporfin Therapy of Subfoveal Choroidal Neovascularization in Age-related Macular Degeneration: Two-year Results of a Randomized Clinical Trial Including Lesions with Occult with no Classic Choroidal Neovascularization—Verteporfin in Photodynamic Therapy,Am. Jour. of Ophthal., May, 2001; 131:541-560.
Farah A.
Minu LLC
Wood, Herrion & Evans, L.L.P.
LandOfFree
Method to treat age-related macular degeneration does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method to treat age-related macular degeneration, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method to treat age-related macular degeneration will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3397848